The Company expects to submit the New Drug Application for Xulane Lo in the second half of 2025. A low dose combination hormonal patch was found to be effective for pregnancy prevention based on ...
PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive ...
Shorter-acting birth control options must be maintained on a more regular basis, from daily to tri-monthly. The birth control patch (norelgestromin/ethinyl estradiol) must be applied weekly. Options ...
"We are pleased with the profile our investigational XULANE LO low dose patch demonstrated in this Phase 3 study," said Viatris Chief R&D Officer Philippe Martin. "The data underscores our confidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback